Japan Activation Capital Discloses 6.2% Stake in Nihon Kohden

Japan Activation Capital disclosed a 6.20% stake in Nihon Kohden Corporation on Tuesday, formalizing a large position that the investment firm acquired five days earlier. The filing shows JAC holding 10,414,800 shares of the Tokyo-listed medical-device maker after an off-market purchase on September 10 at ¥1,350 per share.

The disclosure adds regulatory detail to an investment Nihon Kohden and JAC had already announced alongside a strategic partnership. Their September 10 announcement described the same 10,414,800 shares as 6.48% of Nihon Kohden’s voting rights, a higher percentage than the 6.20% ownership figure in the new large-shareholding report because the two disclosures use different denominators.

The EDINET large-shareholding report, filed with the Kanto Local Finance Bureau on September 15, lists Japan Activation Capital as the sole reporting holder. It says the shares are held as a pure investment under limited-partnership arrangements, while also stating that JAC intends to support the execution of management strategy and organizational strengthening through dialogue with Nihon Kohden’s management.

Why the filing says 6.20% while Nihon Kohden said 6.48%

The two percentages describe the same block of shares in different ways. JAC’s EDINET filing uses 167,961,960 issued shares as of September 10 as the denominator for its large-shareholding calculation, producing a 6.20% ownership ratio for the 10,414,800 shares it reports holding.

Nihon Kohden’s earlier notice used the company’s 1,608,428 voting rights as of March 31 and calculated JAC’s position at 6.48% of total voting rights. Voting-rights percentages do not use the same denominator as a percentage based on issued shares, so the 6.20% and 6.48% figures are not competing estimates of how many shares JAC bought. Both official disclosures identify exactly 10,414,800 shares.

The EDINET report also breaks the position across three investment vehicles managed by JAC. Japan Activation Capital I L.P. holds 5,445,700 shares, Japan Activation Capital II Alpha L.P. holds 4,927,600, and JAC Joint Investment Fund No. 8 Investment Limited Partnership holds 41,500. The filing reports ¥14.055651 billion of acquisition funding from fund capital and does not list borrowed money for the purchase.

JAC reported no “important proposal acts” in the filing, which means the document does not disclose a formal proposal of the type covered by that section of Japan’s large-shareholding regime. The stated purpose is more engaged than a purely hands-off portfolio position: the filing explicitly pairs its “pure investment” classification with support for management strategy and organizational strengthening through a trust-based dialogue.

Strategic partnership gives the stake an operating role

Nihon Kohden and JAC announced their strategic partnership on September 10, the same day the shares were acquired. Nihon Kohden said it plans to use JAC’s resources, know-how and network, while JAC will act as a shareholder and strategic partner supporting medium- to long-term growth.

The partnership arrives as Nihon Kohden approaches the end of BEACON 2030 Phase II, the three-year business plan that runs through the current fiscal year. Chief Executive Hirokazu Ogino said the company has made progress on growth and profitability reforms but still faces work to reach its March 2030 goals, including a 15% operating profit margin and a 45% overseas sales ratio. He identified faster growth in North America, expansion of the solutions business and a deeper focus on profitability as priorities for the next stage.

JAC’s Hiroyuki Otsuka placed particular emphasis on Nihon Kohden’s Digital Health Solutions business. In the partnership announcement, he pointed to software and service opportunities around remote monitoring, alarm management, clinical decision support and automated anesthesia, as well as the broader use of data generated by medical devices and sensors. JAC also said it sees room to improve domestic cash generation, overseas growth, predictability of business performance and communication with capital markets.

JAC’s own description of its investment model matches that role. The firm says it invests in listed Japanese companies and works with management teams through long-term, engagement-oriented partnerships rather than limiting its role to holding shares. The Nihon Kohden announcement put JAC’s fund assets under management at approximately ¥235 billion as of August 31, including commitments for co-investment.

Nihon Kohden is trying to restore profit momentum

Nihon Kohden’s latest quarter shows the profit challenge facing management. The company reported first-quarter sales of ¥47.405 billion for the three months ended June 30, down 5.2% from a year earlier. Domestic sales fell 15.0% to ¥26.080 billion, while international sales increased 10.3% to ¥21.325 billion.

Profitability weakened more sharply. The company posted an operating loss of ¥983 million for the quarter, compared with operating income of ¥1.4 billion a year earlier, and attributed the deterioration to lower domestic sales and higher selling, general and administrative expenses associated with wage increases. Nihon Kohden also recorded a ¥756 million loss attributable to owners of the parent, versus a ¥137 million profit in the prior-year quarter.

Management reaffirmed its full-year forecast in August. For the fiscal year ending March 2027, Nihon Kohden expects net sales of ¥232.5 billion, down 1.1% year over year, and operating income of ¥23.5 billion, up 25.4%. The company expects domestic medical-institution spending to improve later in the fiscal year and has said it is pursuing groupwide profit-structure reforms while continuing investment in growth areas.

JAC’s new filing adds the regulatory ownership ratio, the investment vehicles holding the shares, the funding source and the stated purpose of the position. Those details arrive as Nihon Kohden works through a first-quarter operating loss and prepares its next three-year plan. Nihon Kohden’s next scheduled earnings release is November 10, followed by an investor-relations meeting on November 11, providing the next formal update on the company’s operating progress.